Back to Susquehanna International Group, LLP Susquehanna International Group, LLP

CLDXCLDX

Showing 8 of 30 quarters

Position history for Susquehanna International Group, LLPSusquehanna International Group, LLP's holdings in Celldex Therapeutics, Inc.

Yes. Susquehanna International Group holds 19,080 shares of CLDX (Celldex Therapeutics), worth $709,967, as of its Q2 2026 13F filing. It reduced the position by 16,868 shares (-46.9%) from Q1 2026. Susquehanna International Group has held CLDX since Q1 2026, across 2 quarterly 13F filings.

Current Value

$709,967

Current Shares

19,080

Total Value Change

-$1.5M

Total Shares Change

-45,496

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
19,080
-46.9%
$709,9670.0%$37.21
0
2026-Q1
New
35,948
—
$1.1M0.0%$31.72
35
2025-Q4
Exited
0
-100.0%
$00.0%$27.16
0
2025-Q3
Decreased
27,367
-75.4%
$707,9840.0%$25.87
0
2025-Q2
Increased
111,399
+18.9%
$2.3M0.0%$20.35
31
2025-Q1
Increased
93,670
+41.9%
$1.7M0.0%$18.15
34
2024-Q4
Increased
66,034
+2.3%
$1.7M0.0%$25.27
26
2024-Q3
Increased
64,576
+35.0%
$2.2M0.0%$33.99
34

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used